MAPT and Alzheimer disease: In a phase 2 trial in subjects with mild to moderate AD, resveratrol, given orally in a daily dose of 0.5–1 gm, had no effect on plasma Aβ42, CSF Aβ42, CSF tau, CSF phospho-tau181, hippocampal volume, entorhinal cortex thickness or different measures of cognitive function and even significantly reduced whole brain volume [91].